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ABSTRACT 
BACKGROUND 
There is mounting evidence that 
Parkinson's disease causes significant 
disability and impairs health-related 
quality of life. However, this dimension 
has not been fully characterised, 
particularly among Africans. We 
examined the generic and disease-
specific health related quality of life 
profiles of Nigerian Africans with 
Parkinson's disease in comparison to 
demographically-matched controls. 
METHODS 
Thirty-six consecutive Nigerian patients 
with Parkinson's disease were assessed 
using a battery comprising of the 
Parkinson's disease questionnaire-39 (a 
disease-specific instrument), and the EQ-
5D (a generic instrument whose 
maximum score of 1.00 indicates best 
quality of life). A structured 
questionnaire interview and a complete 
neurological examination including the 
Hoehn and Yahr stage of illness scale and 
the motor section of the Unified 
Parkinson's Disease Rating Scale were 
performed on the same day. Thirty-
sixages and gender- matched apparently 
healthy controls were also assessed. 
RESULTS 
There was no significant difference in 
age between the patients (64.3 + 10years) 
and controls (63. 7 + 9 years). The patients 
had significantly poorer EQ-5D score 
(0.31 + 0.23) compared to the controls 
(0.84+ 0.12 for the controls, P< 0.001). The 
Parkinson's disease questionnaire-
39demonstrated poor quality of life in 
patients with the poorest performances in 
the mobility, activities of daily living and 
emotional well-being dimensions. 
However the social support dimension 
was not impaired. 
CONCLUSION 
Patients with Parkinson's disease had 
much poorer generic and specific health 
related quality of life in comparison to 
their healthy counterparts. Management 
should be multi disciplinary in order to 
holistically improve quality of life in all 
affected domains. 
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INTRODUCTION 
More than 180 years ago, James Parkinson 
first described the disorder that bears his 
name. Parkinson's disease (PD) is one of the 
most common neurodegenerative diseases of 
insidious onset in middle or late age1• 
Mortality is two to five times as high among 
affected persons as among age-matched 
controls24, resulting in a marked reduction in 
life expectancy6.1ndeed, neurodegenerative 
diseases including PDare projected to surpass 
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cancer as the second most common cause of 
death among the elderly by the year 20405• PD 
as described by James Parkinson, was thought 
to cause only motor symptoms. Non-motor 
features particularly the psychosocial 
manifestations, which can be more disabling 
than the motor symptoms themselves, are 
ignored. Patients with PD do suffer 
restrictions in mobility, falls, emotional 
disorders, depression, psychosis, cognitive 
impairment, social embarrassment, isolation, 
sleep disturbances, and fluctuations 6 • 
Therefore, there is mounting evidence that PD 
can cause significant disability, impairing 
physical, emotional, psychological and 
socioeconomic functioning thereby reducing 
health-related quality oflife (HRQOL)6-12• 
However, the concept of HRQOL in PD is 
relatively new. So the actual impact of PD on 
different domains of HRQOL has not been 
fully characterised, particularly among 
Africans. The descriptions in literature are 
mostly incomplete and inconsistent. Few 
studies have concurrently explored the impact 
of PD on generic and specific HRQOL m 
comparison to matched healthy controls. 
Therefore, we aimed to examine the HRQOL 
profiles of Nigerian Africans with PD in 
comparison to demographically-matched 
controls using both generic and disease-
specific instruments. We hypothesized that 
PD patients will have worse HRQOL than 
their healthy counterparts. 
METHODS 
Subjects 
We studied 36 patients with clinical diagnosis 
of PD who were consecutively recruited in 
2009 from the Neurology outpatient clinic of 
the University of Port Harcourt Teaching 
Hospital (UPTH), Nigeria. The diagnosis ofPD 
was based on the United Kingdom (UK) 
Parkinson's Disease Society Brain Bank 
Clinical Diagnostic Criteria[13,14]. Patients 
with history of stroke, significant head injury, 
previous encephalitis, drug and alcohol abuse 
were excluded. Those on neuroleptic 
treatment, methyl- dopa and reserpine at the 
onset of symptoms were also excluded. Other 
patients with Parkinsonism plus syndromes, 
cognitive impairment before 1 year of onset, 
supranuclear gaze palsy, cerebellar signs or 
negative response to levodopa were excluded. 
Thirty-six controls matched for age and sex 
were recruited. For every patient, we looked 
for a control with the same gender and age +1- 2 
years. They comprised apparently healthy 
volunteers without Parkinsonism or any other 
known medical or psychological disease. 
Informed written consent was obtained from 
all recruited subjects. Ethical approval to 
undertake the study was obtained from the 
UPTH Ethics Committee. 
Sample size estimation 
The minimum sample size of patients required 
for the study was 28, calculated based on the 
method of Kish 15• The standard normal 
deviation (z) was set at 1.96, which 
corresponds to the 95% confidence interval. 
The proportion of patients with PD (p) was 
estimated at 59 per 100,000 [16], while the 
absolute deviation from p% that will be 
tolerated (d) was set at 0.009. 
Instruments 
The Parkinson's disease questionnaire- (PDQ-
39) [17]. The PDQ-39, comprising 39 items, is 
the most widely validated and most widely 
used disease specific instrument employed in 
studies of PD patients17-20 • It has eight 
subscales/dimensions: mobility (10 items), 
activities of daily living (6items), emotional 
well being (6 items), stigma (4 items), social 
support (3 items), cognition (4 items), 
communication (3 items) and bodily 
discomfort (3 items). Items in each subscale, as 
well as in the total scale, can be summarized 
into an index and transformed linearly to a 0-
100 scale17'19• Higher scores indicate poorer 
health-related quality oflife. 
Euroqol-5d (EQ-5Dl1 
The EQ-5D is a short generic HRQOL 
questionnaire with five questions on mobility, 
self-care, pain, social activities, and 
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psychological status and three possible 
answers for each item (1=no problem; 2= 
moderate problem: and 3= extreme problem)21• 
A summary index with a maximum score of 1 
can be derived from these five dimensions by 
conversion with a table of scores. The 
maximum score of 1 indicates the best health 
state, in contrast to the scores of individual 
questions, where higher scores indicate more 
severe or frequent problems. In addition, it has 
a Visual Analogue Scale (VAS) to indicate the 
general health status with 100 indicating the 
best health status. 
Test procedure 
We conducted a pilot study among 10 patients 
and 10 matched controls to validate PDQ-39 
version 1.1 which had not been validated in 
Nigeria. Those who participated in the pilot 
study were similar to overall sample in terms 
of age, sex and marital status. To assess its 
test-retest reliability the PDQ-39 was 
administered twice to the patients at an 
interval of one week to minimize the subjects' 
recall of the previous answers. 
Subsequently, consecutive eligible patients as 
well as age- and sex-matched controls were 
assessed using standardized questionnaires to 
obtain demographic information, medical 
history, previous psychiatric history and 
history of use of alcohol consumption. The 
questionnaire also assessed disease-related 
variables such as age at onset of disease, 
duration of the disease, duration of treatment 
and profile of motor and non-motor features of 
PD. 
On the same day of the clinic visit a detailed 
neurological examination was performed on 
the patients to verify the clinical diagnosis of 
PD. The stage and severity of the disease was 
determined by using the Hoehn and Yahr 
staging scale22 and the motor part of the 
Unified Parkinson's Disease Rating Scale 
(UPDRS?3 • Thereafter, all recruited patients 
had a complete HRQOL battery consisting of 
the PDQ-3917 and EQ-5D21 administered to 
them. The EuroQOL-5D is a widely used 
generic quality of life instrument allowing 
comparisons between different patient groups 
and the general population. It was validated 
briefly and administered to the control group 
as well. 
All questionnaires were administered in 
English language, a language spoken and 
understood by eligible patients. 
Statistical analysis 
Summary and dimension scores of the various 
instruments were calculated according to their 
individual scoring algorithms 17 ' 21 • 
Psychometric attributes were generated from 
the pilot study using standard techniques. 
Internal consistency was assessed by 
Cronbach's alpha and item-total correlations. 
The criteria for acceptability included a 
Cronbach's alpha of > 0. 70 and item-total 
correlations >0.30 [17]. Test-retest reliability 
which measured the stability of the 
instrument was assessed using the product-
moment correlation between individual 
participant's test scores and retest scores. A 
correlation coefficient of >0.75 was deemed 
acceptable17• 
Construct validity was assessed by examining 
the correlation of the overall PDQ-39 score to 
the EQ-5D and its VAS scale. The difference in 
mean scores between the sample of patients 
with Parkinson's disease and the reference 
population were tested using the Students t-
test. Chi square tests were used for categorical 
variables. A P-value of 0.05 or less was 
considered statistically significant. Data was 
analysed using the SPSS version 15.0 
RESULTS 
Demographic characteristics 
The sample consisted of 36 patients with 
Parkinson's disease (PD) and 36 healthy 
controls, comprising 27 men and 9 women in 
the PD group while the control group consisted 
of 28 men and 8 women. There was no 
significant difference in the mean age of the 
patients with PD (64.3 + 10.9 years) compared 
to controls (63. 7 + 9.2years)(P = 0.83). 
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More than half of both groups were married 
(77.8% and 83.3% respectively). Fifteen 
(41.7%) PD patients as against 24 (66.7%) 
controls were in paid employment. More than 
half of the PD subjects ( 58.3%) were retired. 
Clinical characteristics 
The mean age at onset ofPD was 60.8 years ( + 
10.5years) with a range of 39-80 years. The 
onset was before the age of 60 years in sixteen 
( 44.4%) patients. 
The mean Hoehn and Yahr stage was 3.19(+ 
0.6) while the mean UPDRS score was 44.3 ( + 
14.2) (table 2).The mean duration of PD was 
3.5 (+ 3.1)years. Twenty-five (69.4%) patients 
had had the disease for more than 2 years and 
about the same number (24 (66.7%) had been 
on treatment for a year or more. 
Psychometric parameters ofPDQ-39 
PDQ-39 demonstrated good content validity 
because it reflected most of the key aspects of 
HRQOL that were important and specific to 
the patients themselves. It comprised 
subscales that represent the physical, 
functional, psychological, and social domains 
of life. However, many of the patients had 
additional concerns regarding finance which 
are not covered by the instrument (PDQ-39). 
Construct validity was demonstrated by the 
significant correlation between the overall 
score for PDQ-39 and EQ-5D (r= -0.47, 
P=0.004) and its Visual AnalogueScale (VAS) 
(r=-0.49, P=0.003). 
The Cronbach's alpha for the 8 multi-item 
subscales ranged from -0.02 (social support) to 
0.88 (stigma) while the cronbach's alpha for 
the overall PDQ-39 score was 0.98 (Table 1). 
Test-retest reliability coefficient (Pearson's 
correlation coefficient) was high for stigma 
(r=0.95), emotional well being (r=0.89), 
cognitive impairment (r=0.86) and bodily 
discomfort (r=0.82) domains as well as the 
overall PDQ-39 (r=0.96)(see Table 2). 
Profile of HRQOL scores among patients with 
PD and control subjects. There was significant 
difference in EQ-5D score between PD 
patients (0.31+ 0.23) and controls (0.84 + 
0.12)(t =12.304,P= <0.001)(Table 3). 
There was also significant difference in the 
VAS score for PD patients (43.4+9. 7) compared 
with controls (77.6 + 13.4) (t =12.447, P = 
<0.001). Among the patients, the mean scores 
for mobility, ADL and emotional well being 
were the highest. 
Table 1: Clinical characteristics of study 
subjects 
Characteristics Frequency % Range(years) MeantSD 
Age at onset of disease 
(years) 16 44.4 39-80 60.8 + 10.5 
Lessthan60 20 55.6 
60andabove 
Duration of disease 
Less than 2 years 11 30.6 0.4-14 3.5 + 3.1 
2 years or more 25 69.4 
Duration of 
treatment(years) 12 33.3 0.02-9 2.0 + 2.3 
Less than 1 year 24 66.7 
1 year or more 
Severity ofPD 
Hoehn and Yahr 
Stage I 0 0 
Stage II 2 5.6 
Stage III 26 72 
Stage IV 7 19.4 
Stage V 1 2.8 
UPDRS(motor part) 44.3 + 14.2 
Table 2: Rehabiiity, Test-retest and 
Variability of PDQ-39 for patients with 
Parkinson's disease 
Scale No of Cronbach's Test- Mean SD Observed 
items Alpha(N=36) retest score Range 
(N=10) 
Mobility 10 0.78 0.65 63.0 19.34 22.5-100 
Activities of 6 0.79 0.50 61.80 23.45 16.67-
daily 100 
Living 
Emotional well- 6 0.72 0.89 67.31 18.23 29.16-
Being 100 
Stigma 4 0.88 0.95 58.51 58.51 0-100 
Social Support 3 -0.02 0.32 12.96 12.96 0-50 
Cognitive 4 0.64 0.86 39.93 39.93 0-100 
impairment 
Communication 3 0.72 0.26 42.59 42.59 0-100 
Bodily 3 0.56 0.82 58.24 58.24 0-100 
discomfort 
PDQ-39 39 0.98 0.96 49.91 13.66 22.45-
Overall Score 81.46 
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Table 3: Comparison of PDQ-39 (overall and 
subscale scores), EQ-5D and VAS scores 




EuroQOL-5D 0.31 t 0.23 
Visual Analogue 43.4 t 9.7 
Scale 
Overall PDQ-39 49.9 t13.7 
Mobility 63 t 19.3 
Activities of 61.8 t 23.5 
daily living 
Emotional 67.3 t 18.2 
wellbeing 
Stigma 58.5t 33.7 
Social support 13t 14.9 
Cognitive 39.9t 23.1 
impairment 
Communication 42.6t 25.4 




















0.84 t 0.12 
77.6 t 13.4 
t p value 
12.304 < 0.001 
12.447 < 0.001 
The concept of quality oflife is ambiguous and 
still evolving particularly in Nigeria, where-
"to the best of the authors' knowledge"- no 
study on quality of life in PD was carried out 
prior to this study. In addition to a generic 
measure, we utilised the PDQ-39 which 
showed acceptable psychometric attributes. 
Psychometric attributes of the PDQ-39 
The PDQ-39 assessed most of the physical, 
functional, psychological, and social concerns 
of the people with PD. However, its content 
validity will likely be enhanced by the 
adjustment of items in the social support 
subscale to include relationship of the subjects 
with extended family members. This appears 
to be a more important area of concern to the 
PD population in Port Harcourt and in other 
parts of the developing world where the 
extended family system is still strong. 
Personal finances were also important issues 
for many of the subjects, but an argument 
against their inclusion in the assessment of 
HRQOL is that these areas are encompassed 
by general QOL and fall outside the purview of 
HRQOL24,25. 
The PDQ-39 demonstrated good construct 
validity by its overall score correlation with 
mean scores of EQ-5D and its VAS. The high 
correlations, demonstrated by the scale, 
between items of the same subscales, and 
between the subscales and the overall scale, 
suggest that the items and the subscales 
measure the same construct. 
Five of the subscales of the PDQ-39 and the 
overall scale demonstrated good internal 
consistency comparable to the levels reported 
by the original developers of the inventory. 
However, the social support (-0.02), cognitive 
impairment (0.64) and bodily discomfort (0.56) 
subscales had Cronbach's alpha values lower 
than 0.70. Similar results were reported in a 
study conducted to validate the Spanish 
version of the PDQ-39 which showed that 
Cronbach's alpha for social support and 
cognition domains were beneath ideal values26. 
This calls to question the concept underlying 
these domains particularly the social domain 
in developing countries like Nigeria where 
support from extended family members is 
considered very crucial. 
The low Cronbach's alpha value for the 
cognition and bodily discomfort subscales 
could probably be accounted for by lack of 
clarity of some of their items. In the cognition 
domain for example, item 4 ("Had distressing 
dreams or hallucinations?") could be better 
stated in simpler terms. In addition, subscale 
weighting should be revised for different 
populations because level of importance of 
different subscale differs from culture to 
culture26. 
Test retest reliability was generally high in 
agreement with values reported by the 
developers of the PDQ-3917• 
Profile of HRQOL among PD patients in 
Nigeria 
This is the first study providing both generic 
and disease-specific HRQOL profile of patients 
with PD in comparison with apparently 
healthy controls in Africans. 
Most studies used generic inventories alone 
which do not address key areas of concern in 
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patients with PD11'27• The use of PD-specific A similar result was obtained in a study ofPD 
instrument is more sensitive to the nuances of patients attending a neurology clinic in the UK 
the disease and addresses major areas of [31]wherethe non-clinic attendees had worse 
concern from the patient's perspective17• Few HRQOL in the mobility, ADL and emotional 
studies used disease-specific instruments well-beingdomains. 
alone or in combination with generic 
instruments27'28• Furthermore, fewer studies 
had examined HRQOL in adults with PD in 
comparison with a reference healthy 
population 11'12• 
One of such studies was conducted by The 
Global Parkinson's Disease Survey (GPDS) 
Steering Committee which undertook a cross-
sectional, random, multicenter international 
survey of patients with PD, their care-givers, 
and clinicians. They conducted face to face 
interviews with subjects in six countries and 
recruited 1,020 patients with PD to represent 
PD population in these countries29• Since no 
African country was involved, one can argue 
that due to cultural differences, the profile of 
HRQOL in PD patients may differ among 
Africans, thus justifying this study. 
In our study, PD patients clearly 
demonstrated poorer HRQOL than their 
healthy counterparts. This has been a fairly 
constant finding in studies that have 
compared HRQOL in both groups, irrespective 
of culture, race or country's resource 
status9'24'27'28'31• The mean index score of the EQ-
5D in patients with PD was about one third 
that of the control group. This is similar to 
what was reported by Shrag et al28• All the 
spheres of daily life (mobility, self-care, ADL, 
etc) were affected compared to the control 
group in which pain/discomfort were the major 
complaints. 
The large difference of HRQOL between the 
healthy control group and the patients with 
PD was also seen in the VAS of the EQ-5D. 
In agreement with previous studies 
[12,28],HRQOL in patients with PD was also 
found to be poor in this study using the PDQ-
39. Most domains of HRQOL were affected 
including mobility, ADL and emotional well 
being which demonstrated the worst HRQOL. 
In our study, the social support dimension of 
the PDQ-39 was relatively spared. This is 
probably because in Africa, the extended 
family system still operates such that most 
patients would have adequate support from 
their close relatives as well as members of the 
extended family. This preservation of the 
social domain of the HRQOL is supported by 
Fitzpatrick et aP1 who found that social 
support, as measured by the PDQ-39, is less 
strongly related to clinical assessments of 
disease severity. This implies that the 
individuals' with close ties and support from 
their spouse and partners are less affected by 
disease severity. However, due to poor 
reliability of the PDQ-39 in this subscale, new 
instruments should be developed to confirm 
these findings. 
Limitations 
The PDQ-39 lacks items on self-image, night 
time sleep problems, sexual activity and 
finances which were major concerns for our 
patient. It also did not adequately assess some 
of the domains particularly the social domain. 
However the PDQ-39 is the scale that has been 
most tested and used in the largest number of 
studies and has adequate clinometric 
characteristics which warranted its use in this 
study. 
CONCLUSION 
The PDQ-39 demonstrated an overall 
moderate internal consistency reliability, good 
test-retest reliability and satisfactory 
construct validity among Nigerian Africans 
with PD. However more items are needed to 
enhance its content validity and reliability 
particularly in the social domain. Nigerian 
Africans patients with PD (EuroQOL-
5d=0.31) had severely impaired generic 
HRQOL compared to apparently healthy 
controls (EuroQOL-5D=0.83). Most of the 
impairment manifested in mobility, emotional 
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well-being and ADL domains. However the 
social support domain was relatively spared 
probably due to support from members of the 
extended family. In the management of PD 
patients, holistic care targeted at improving 
mobility, emotional well being and 
performance of ADL is required to improve 
their HRQOL. 
REFERENCES 
1. Lang AE and Lozano AM. Parkinson's 
disease. First of Two Parts. Review 
Articles. N Eng J Med 1998; 339:1044-
1053. 
2. Bennett DA, Beckett LA, Murray AM, 
Shannon KM, Goertz CG, PilgrimDM et 
al. Prevalence of Parkinsonian signs and 
associated mortality Ina community 
population of older people. N Eng J Med 
1996; 334:71-76. 
3. Morens DAM, Davis JW, Grandinetti A, 
Ross GW, Popper JS, White 
LR.Epidemiologic observations on 
Parkinson's disease: incidence and 
mortality in prospective study of middle-
aged men. Neurology 1996; 46:1044-
1050. 
4. Louis ED, Marder K, Cote L, Tang M, 
Mayeux R. Mortality from Parkinson's 
disease. Arch Neurology 1997; 54:260-
264. 
5. Lilienfeld DE, Perl DP. Projected 
Neurodegenerative disease mortality 
inthe United States, 1990-2040. 
Neuroepidemiology 1993; 12:219-228. 
6. .Martinez - Martin P. An introduction to 
the concept of "quality of life In 
Parkinson's disease". J Neurol1998; 245 
(suppl1): 52- 56. 
7. Akinyemi RO, Okubadejo NU, Akinyemi 
JO, Owolabi MO, Owolabi FO,Ogunniyi 
A. Cognitive Dysfunction in Nigerians 
with Parkinson's disease, Movement 
Disorders 2008; 23(10): 1378-1383. 
8. Shrag A. Quality oflife and depression in 
Parkinson's disease. JThe Neurological 
Sci 2006; 248:151-157. 
9. ShragA,JahanshashiM,QuinnN. What 
contributes to quality of life inpatients 
with Parkinson's disease? J 
N eurolN eurosurg Psychiatry 2000; 69: 
308-312. 
10. Okubadejo NU, OjiniFl, Danesi MA. 
Longitudinal study of 
mortalitypredictors in Parkinson's 
disease in Nigerians. Afr J Med 
MedSci2005; 34: 365-369. 
11. Kuopio A, Martilla RJ, Helenius H, 
Toivonen. The quality of life 
inParkinson's disease. Movement 
disorders 2000; 15(2 ): 216-223. 
12. Koplas PA, Gans HB, Wisely MP, 
Kuchibhatla M, Cutson TM, Gold DTet al. 
Quality of life and Parkinson's disease. J 
Gerontology series A,Biological sciences 
and medical sciences 1999; 54(4): 197-
202.(abstract) 
13. Hughes AJ, Daniel SE, Kilford L, Lees 
AJ. Accuracy of Clinical diagnosis of 
idiopathic Parkinson's disease. A Clinico-
pathological study of 100 cases. J 
N eurolN eurosurg Psychiatry 1992; 55 
(3): 181-184. 
14. Bhatia KP, Burn DJ, Goetz CG, Lang AE, 
Mckeith I et al. Movement disorder 
society scientific issues committee report: 
SIC Task force appraisal of Clinical 
diagnostic Criteria for Parkinsonian 
disorders. Movement disorder 2003; 18: 
467-486. 
15. Kish L. Survey sampling. New York: John 
Wiley and Sons; 1965. 
16. Schonberg BS, Osuntokun BO, Adeuja 
AOG, BademosiO, Nottidge V, Anderson 
DW, Haerer AF. Comparison of the 
prevalence of Parkinson's disease in 
black populations in rural United States 
and in rural Nigeria: Door-to-door 
community studies. Neurol1988; 38: 645-
646 
17. Jenkinson C, Fitzpatrick R, Peto V, 
Harris R, Saunders P. TheParkinson's 
Disease Questionnaire PDQ -39 User 
manual. Oxford: publisher 2008 Pg 1-
50,75-79. 
18. Maurinus J, Visser M, Jenkinson C, 
Stiggel bout AM. Health related quality 
of life in Parkinson's disease: a 
systematic review of disease specific 
instruments. J Neurology Neurosurgery 
The Nigerian Health Journal, Vol. 14, No 2, April- June, 2014 IPagel:fj 
Generic and Disease-Specific Health-Related QOLin Parkinson's Disease - Okunoye CO, et al 
Psychiatry 2002; 72; 241-248. 
19. Heffernan C, Jenkinson C. Measuring 
outcomes of four neurological disorders: a 
review of disease-specific Health status 
instrument for three degenerative 
neurological conditions. Chronic illness 
2005; 1:131-142. 
20. Damiano AM, Snyder C, Strausser B and 
William. A review of health related 
quality of life concepts and measures for 
PD. Qual life Res 1999; 8: 235-243. 
21. Schrag A, Selai C, Jahanshashi M, Quinn 
N .The EQ-5D- a generic quality of life 
measure - is a useful instrument to 
measure Quality of life in patients with 
Parkinson's disease. J NeurolNeurosurg 
Psychiatry 2000; 69; 67-73. 
22. Hoehn MM and Yahr MD. Parkinsonism: 
onset, progression and mortality. J. 
Neurology 1967; 17:427-442. 
23. Goetz CG, Fahn S, Martinez-Martin P, 
Poewe W, Sampaio C, Stebbins GT et al. 
Movement Disorder Society-sponsored 
revision of the Unified Parkinson's 
Disease Rating Scale (MDS-UPDRS): 
process, format, and clinimetric testing 
plan. MovDisord2007; 22:41-47. 
24. Gage H, Hendricks A, Zhang S, Kazis L. 
The relative health related quality of life 
of veterans with Parkinson's disease. J 
NeurolNeurosurg Psychiatry. 2003; 
74:163-169. 
25. Karlsen KH, Tandberg E, Arsland D, 
Larsen JP. Health related QOL in PD: A 
prospective longitudinal study. J 
NeurolNeurosurg. Psychiatry2000; 69; 
581-589. 
26. Martinez-Martin P, Payo FB and The 
Grupo Centre for study of Movement 
Disorder. Quality of life in Parkinson's 
disease: Validation study of the PDQ-39 
Spanish version. J Neural 1998; 
245(Suppl1): S34-S38. 
27. Karlsen KH, Larsen JP, Tandberg E and 
Maeland JG. Influence of clinical and 
demographic variables on quality of life 
in patients with Parkinson's disease. J 
Neural. Neurosurg. Psychiatry 1999; 
66:431-435 
28. Shrag A, Jahanshahi M, Quinn N. How 
Does Parkinson's disease affect Quality of 
life? A comparison with quality of life in 
the General population. Movement 
Disorders 2000; 15(6): 1112-1118. 
29. The Global Parkinson's Disease Survey 
(GPDS) Steering Committee. Factors 
Impacting on QOL in PD: Results from an 
International survey. Mov Dis 2002; 
17:60-67. 
30. Reese SL. Psychosocial factors in 
Parkinson's disease. Dis Mon. 2007; 
53:291-295. 
31. Fitzpatrick R, Peto V, Jenkinson C, 
Greenhall R, Hyman N. Health- related 
Quality of life in Parkinson's Disease: A 
Study of Outpatient Clinic Attenders. 
Movement disorders 1997;12:912-922. 
The Nigerian Health Journal, Vol. 14, No 2, April- June, 2014 IPagel;{j 
